These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3747914)

  • 21. [Should drug prescriptions be modified in cirrhotic patients?].
    Attali P
    Presse Med; 1986 Oct; 15(33):1661-3. PubMed ID: 2947110
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers.
    Drouet-Coassolo C; Iliadis A; Coassolo P; Antoni M; Cano JP
    Fundam Clin Pharmacol; 1990; 4(6):643-51. PubMed ID: 2096104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
    Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
    Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver disease and drug therapy.
    Black M
    Med Clin North Am; 1974 Sep; 58(5):1051-7. PubMed ID: 4608944
    [No Abstract]   [Full Text] [Related]  

  • 26. Biliary excretion of drugs and other xenobiotics.
    Levine WG
    Prog Drug Res; 1981; 25():361-420. PubMed ID: 6273968
    [No Abstract]   [Full Text] [Related]  

  • 27. Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease.
    Hepner GW; Vesell ES
    Clin Pharmacol Ther; 1976 Dec; 20(6):654-60. PubMed ID: 991536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Liver- and drug metabolism].
    Schmid E; Ritter U
    Dtsch Med J; 1971 Nov; 22(22):695-7. PubMed ID: 5134616
    [No Abstract]   [Full Text] [Related]  

  • 29. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.
    Naranjo CA; Busto U; Janecek E; Ruiz I; Roach CA; Kaplan K
    Br J Clin Pharmacol; 1983 Apr; 15(4):451-8. PubMed ID: 6849781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of liver disease on drug disposition in man.
    Wilkinson GR; Schenker S
    Biochem Pharmacol; 1976 Dec; 25(24):2675-81. PubMed ID: 795432
    [No Abstract]   [Full Text] [Related]  

  • 31. Clearance by the liver: current concepts in understanding the hepatic disposition of drugs.
    Larrey D; Branch RA
    Semin Liver Dis; 1983 Nov; 3(4):285-97. PubMed ID: 6359424
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of cholestasis on drug elimination: pharmacokinetics.
    Harrison LI; Gibaldi M
    J Pharm Sci; 1976 Sep; 65(9):1346-8. PubMed ID: 966151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.
    Le Couteur DG; Fraser R; Hilmer S; Rivory LP; McLean AJ
    Clin Pharmacokinet; 2005; 44(2):187-200. PubMed ID: 15656697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of bile acids and some biliary excreted drugs on the metabolism of cortisol.
    Gerdes H; Riemenschneider H; Littmann KP
    Acta Endocrinol Suppl (Copenh); 1973; 173():10. PubMed ID: 4542050
    [No Abstract]   [Full Text] [Related]  

  • 35. [Metabolism of clofibrate in hepatitis and liver cirrhosis].
    Hartlapp JH; Kürten J; Gugler R
    Verh Dtsch Ges Inn Med; 1978; (84):1108-10. PubMed ID: 741896
    [No Abstract]   [Full Text] [Related]  

  • 36. Commentary: a physiological approach to hepatic drug clearance.
    Wilkinson GR; Shand DG
    Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Liver Disease on Hepatic Transporter Expression and Function.
    Thakkar N; Slizgi JR; Brouwer KLR
    J Pharm Sci; 2017 Sep; 106(9):2282-2294. PubMed ID: 28465155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dangerous drugs in hepatic insufficiency].
    Isal JP; Caulin C
    Med Chir Dig; 1979; 8(5):447-9. PubMed ID: 534025
    [No Abstract]   [Full Text] [Related]  

  • 39. Aminoacid imbalance ratio in liver disease.
    Maqsood R; Zuberi SJ
    J Pak Med Assoc; 1976 Jun; 26():145-6. PubMed ID: 824473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Blood fructose and urinary fructose in diabetes mellitus and in various types of liver damage].
    Mierwa-Homerska S
    Pol Tyg Lek; 1983 Jan; 38(4):109-12. PubMed ID: 6682972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.